Dr. Reddy's Laboratories Ltd. · NSE:DRREDDY
Dr. Reddy's Laboratories — Investor Presentation (2011)
20 slides from Dr. Reddy's Laboratories's investor presentation, Oct 14, 2011
Slide 1: The Dr. Reddy's story
e ¢ Y Dr. REDDY'S The Dr. Reddy’s story Lit PORES EAM GH, om OF
Slide 2: Outline
Outline Our Purpose and Strategy The journey so far: Key Milestones Dr. Reddy Reddy’ss today Key Questions www.drreddys.com 2
Slide 3: Our Purpose and Strategy
Our Purpose and Strategy Purpose Providing affordable and innovative medicines for healthier lives Corporate Strategy Leverage industry‐leading science & technology, product offering and customer service to provide affordable and i innovative ti medicines di i for f healthier h lthi lives. li www.dr
Slide 4: Outline
Outline Our Purpose and Strategy The journey so far: Key Milestones Dr. Reddy’s today Key K Questions Q i www.drreddys.com 4
Slide 5: Key Milestones: Taking the First Steps (1984-1990)
Key Milestones Taking the First Steps (1984‐1990) Established bli h d b by Dr K Anjiji Reddy dd with i h an iinitial i i l capital i l outlay l off Rs.25 llakhs kh 1984 Goes public with listing in Bombay Stock Exchange 1986 Enters internationall markets k withh exports off Methyldopa h ld Obtains
Slide 6: Key Milestones: Expanding and Innovating (1991-1999)
Key Milestones Expanding and Innovating (1991‐1999) Formulation l i exports to Russia i commences 1991 1993 Establishes Dr. Reddy's y Research Foundation. Drugg Discoveryy program p g starts Dr. Reddy's Research Foundation files first patent in the US 1995 Becomes first Indian company to out‐licens
Slide 7: Key Milestones: Growing Globally (2000-present)
Key Milestones Growing Globally (2000‐ present) Cheminor Drugs (A group company) merges with Dr. Reddy‘s 2000 Establishes Reddyy US therapeutics p in USA Becomes the first pharma company in Asia Pacific, outside of Japan, to list on NYSE 2001 Obtains 1st ever 180‐day mkt. exclusivity for a gener
Slide 8: Outline
Outline Our Purpose and Strategy The journey so far: Key Milestones Dr. Reddy’s today Key Questions www.drreddys.com 8
Slide 9: Dr. Reddy's Today
Dr. Reddy’s Today Vertically integrated global pharmaceutical company from India Revenue of $1.7 bn in FY10, CAGR of ~25% in the last decade, International (ex‐ India) revenue 40% in FY00 to 81% today Strong portfolio of businesses, geographies and products Three business segments Æ Pharmace
Slide 10: Dr. Reddy's Today: Infrastructure
Dr. Reddy’s Today Infrastructure: 918 manufacturing facilities 8 API manufacturing units (6 FDA‐approved plants in India, 1 FDA‐ approved plant in Mexico, 1 FDA‐approved FDA approved plant in Mirfield, UK) 9 Finished Dosage units (7 Formulation plants in India (2 USFDA approved), 2 USFDA approve
Slide 11: The Last Decade
The Last Decade Built the foundations for a strong business ; Moved up the value chain ; Strengthened capabilities ; Achieved scale & global presence ; Growth aided by acquisitions. Revenues [USD Mn] Germany & Mexico acquisitions Authorized generic launches All figures converted at respective ye
Slide 12: Financial Performance - FY11
Financial Performance- FY11 Revenue Adjusted EBITDA Adjusted PAT USD 1.7 Bn USD 369 Mn USD 242 Mn YOY growth Æ 6% YOY growth Æ 4% YOY growth Æ 17% Revenue Mix by Geography Revenue Mix by Segment Proprietary & Others Others 38 PSAI 229 North America Russia & other CIS 441 522 244 India Global Generic
Slide 13: Our Businesses
Our Businesses Proprietary Products Ph ti l Pharmaceutical Global Generics • Focus on building Services & Active sustainable and profitable • Finished dosage businesses Ingredients in distribution-driven as well branded businesses as doctor doctor-driven driven markets • Customers include generic •
Slide 14: Commitment to Sustainability
Commitment to Sustainability Collective Actions – Our DNA of Sustainability OUR SUSTAINABILITY FRAMEWORK Providing Affordable and Innovative Medicines Environment management and Climate Change Being an Employer of Choice Product Responsibility Sustainable Sourcing Caring for Communities
Slide 15: Dr. Reddy's edge in the pharma space
Dr. Reddy’s edge in the pharma space Industry leading chemistry skills which has resulted in several niche product opportunities (eg: fondaparinux, fexofenadine‐pseudoephedrine, omeprazole mg, lansoprazole) High vertical integration (~75% of APIs sourced internally) Amongst the leading pipeline in f
Slide 16: Outline
Outline Our Purpose and Strategy The journey so far: Key Milestones What is Dr. Reddy’s today Key Questions www.drreddys.com 16
Slide 17: Key Questions
Key Questions 1. What are our aspirations for each business ? 2. Whyy do we believe we will succeed ? www.drreddys.com 17
Slide 18: 1. What are our aspirations?
1. What are our aspirations? Improve depth in key Leadership markets k through h h portfolio f li Global Generics position expansion and supply in key markets chain excellence Pharmaceutical Create compelling value Services for customers by Partner of & Active leveraging IP, technology Choice Ingred
Slide 19: 2. Why do we believe we will succeed?
2. Why do we believe we will succeed? Key K markets k Product Focus Supply S l chain h i delivery & excellence engine Depth Vertical integration with cost, technology & IP leverage www.drreddys.com 19
Slide 20: Thank You
THANK THANK YOU www.drreddys.com
Dr. Reddy's Laboratories — Investor Presentation (2011) on 6ix